Daily Pill Shows Promise in Cutting Heart Failure Risk, Major Trial Finds
A new clinical study reports that oral semaglutide may reduce the risk of serious heart failure events in people with type 2 diabetes. Researchers analyzed data from a large international trial that followed nearly 10,000 adults, and it was seen that participants had type 2 diabetes and either cardiovascular disease or high cardiovascular risk. Scientists tracked their health outcomes for more than four years.
The trial originally examined whether oral semaglutide lowered the risk of major cardiovascular events. Those events included heart attack, stroke, and death from cardiovascular causes. Investigators later conducted a secondary analysis that focused specifically on heart failure outcomes. They wanted to see whether the pill offered additional protection for patients with existing heart failure.
Researchers found that participants with heart failure at the start saw meaningful benefits. Oral semaglutide reduced the combined risk of heart failure hospitalization or death by about 22 per cent. Patients who took the medication experienced fewer serious heart failure events than those who received a placebo. The benefit appeared strongest in people with heart failure with preserved ejection fraction.
Heart failure with preserved ejection fraction, often called HFpEF, remains difficult to treat. In this condition, the heart pumps normally but does not relax properly between beats. Doctors have limited therapies that clearly improve outcomes in this group. The new findings suggest oral semaglutide may offer an important option for these patients.
Not every participant experienced the same benefit. People without heart failure at the beginning of the study did not show a significant reduction in heart failure events. The results suggest the drug may help most when heart failure already exists. Researchers caution that doctors should interpret the findings within that context.
Oral semaglutide belongs to a class of medications known as GLP-1 receptor agonists. These drugs help lower blood sugar by stimulating insulin release and reducing appetite. Many patients also lose weight while taking them. Injectable versions have already shown cardiovascular benefits in earlier trials.
The oral form provides a daily pill alternative to weekly injections. Some doctors believe the pill format may improve adherence for certain patients. Easier dosing could encourage consistent use over long periods. Consistency often plays a key role in reducing cardiovascular risk.
The large trial used a randomized, double blind, placebo controlled design. Participants continued to receive standard diabetes and heart care throughout the study. Researchers randomly assigned them to take either oral semaglutide or a placebo. Neither the participants nor the investigators knew who received the active drug.
During follow up, investigators recorded hospitalizations, deaths, and major cardiovascular events. They carefully reviewed each event to confirm its cause. This approach strengthened the reliability of the results. The large sample size also increased confidence in the findings.
Experts say the study reinforces the growing role of GLP-1 drugs in cardiovascular care. Many people with type 2 diabetes also face high risks of heart disease and heart failure. Doctors often search for treatments that address both blood sugar and heart health. Oral semaglutide appears to support both goals.
Researchers continue to explore how the medication produces these heart benefits. Some scientists suspect weight loss plays an important role. Others point to reduced inflammation and improved blood vessel function. The exact mechanisms still require further investigation.
The findings may influence future treatment guidelines for diabetes and heart failure. Physicians may consider oral semaglutide for patients who already have heart failure and diabetes. However, doctors will still tailor decisions to each patient’s medical history. They must weigh benefits against side effects and costs.
Common side effects of semaglutide include nausea, vomiting, and digestive discomfort. Most symptoms occur early in treatment and often improve over time. Doctors typically start with a lower dose and increase it gradually. This strategy can help patients tolerate the medication more comfortably.
The study adds to a growing body of research that reshapes diabetes care. For years, doctors focused mainly on blood sugar numbers. Today, they increasingly prioritize long term cardiovascular protection. Medications that reduce both glucose and heart risk are meant to change patient outcomes.
Researchers emphasize that lifestyle changes remain essential. Patients should maintain healthy diets, exercise regularly, and follow prescribed treatments. Medications work best when combined with these habits. Comprehensive care offers the strongest defense against complications.
Scientists plan further studies to clarify the drug’s effects in different heart failure subtypes. They also want to examine long-term outcomes beyond the current follow-up period. The ongoing research will help determine how broadly doctors should use the therapy. For now, the results provide cautious optimism for people living with both diabetes and heart failure.
References
Healthline. (2025). Oral semaglutide reduces heart failure risk in people with type 2 diabetes, study finds. Healthline Media. https://www.healthline.com/health-news/oral-semaglutide-reduces-heart-failure-risk-diabetes-study
Novo Nordisk A/S. (2025, March 29). Rybelsus (oral semaglutide) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 [Press release]. GlobeNewswire. https://www.globenewswire.com/news-release/2025/03/29/3051761/0/en/Novo-Nordisk-A-S-Rybelsus-oral-semaglutide-14-mg-demonstrates-superior-reduction-in-cardiovascular-events-in-the-SOUL-trial-at-ACC-2025.html
